Porcilis® PRRS

Live attenuated PRRS virus strain DV: at least 10^4 TCID_50 per dose.

INDICATIONS: For active immunization of clinically healthy pigs in a PRRSV-contaminated environment, to reduce viremia caused by infection with PRRS virus. For fattening pigs, the respiratory tropism is relevant. A significant improvement – reduced morbidity due to PRRS infection, better daily growth, and feed conversion – until the end of the fattening period was observed in vaccinated pigs during field trials. For breeding pigs, the reproductive tropism is relevant. A significant improvement of the reproductive performance of PRRSV-contaminated environment and a reduction of transplacental virus transmission after challenge was observed in vaccinated pigs. The interest of vaccination with Porcilis PRRS lies in a obtaining a heterogeneous and high immune status against PRRSV in a herd. Immunity has been demonstrated via challenge at 28 days post-vaccination. A duration of immunity of at least 24 weeks has been demonstrated.

DOSAGE: Intramuscular injection – 2 ml in the neck. Given to pigs from 2 weeks of age onwards. Use sterile syringes and needles.

PRECAUTION: Care should be taken to avoid the introduction of the vaccine strain into an area where PRRSV is not already present. Care should be taken to avoid spread of vaccine virus from vaccinated animals to unvaccinated animals (e.g. naïve pregnant sows) that should remain free of PRRSV. Do not use in boars producing semen for seronegative herds, as PRRSV may be excreted in semen for many weeks. Do not use in herds where a PRRS eradication programme based on serology has been adopted. PRRSV-naïve gilts and sows should not be vaccinated during pregnancy, as this can be have negative effects. Vaccination during pregnancy is safe when it is performed in gilts and sows which are already immunized against PRRSV via vaccination or field infection. The vaccine can be used during lactation.